Marksans Pharma Limited — Updates, 19-06-2025: Press Release

Marksans Pharma’s UK subsidiary, Relonchem Limited, has secured marketing authorization for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution from UK regulators. This approval strengthens Marksans’ presence in the UK generics market, supporting its growth in respiratory and CNS segments. The addition expands the product portfolio and enhances revenue potential in a regulated market, reflecting ongoing international business development.